Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ERSP reviews hoodia

This article was originally published in The Tan Sheet

Executive Summary

Claims that SmartBurn with Hoodia weight-loss supplement helps control appetite were adequately supported by studies cited by marketer Iovate Health Sciences International, the Electronic Retailing Self-Regulation Program (ERSP) concludes Sept. 5. The company submitted two peer-reviewed, double-blind, placebo-controlled studies to support claims such as "with the key ingredients in SmartBurn, you can lose up to 450% [more] weight than if you were to follow a diet and exercise plan alone." Although the group raised concerns about the use of the word "rapid" to describe the weight loss that took place, it concluded that it was satisfied that consumers would understand the time of product performance being relied on by the marketer in making the claim." An anonymous challenge prompted the review by ERSP...

You may also be interested in...



Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients

As China Rushes Medical Supplies To World, Quality Issues Resurface

As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.

UK Regulator Puts Energies Into COVID-19 While Other Services May Take Longer

With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.

Topics

UsernamePublicRestriction

Register

PS099735

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel